FDA Responds to Dr. Albanese’s April 19, 2021 Letter

The FDA has responded to Dr. Albanese’s letter to them from April 19, 2021.

CLICK HERE to view the response!

FDA Commits to Evidence-Based Actions Aimed at Saving Lives and Preventing Future Generations of Smokers

FDA NEWS RELEASE:
April 29, 2021

FDA Commits to Evidence-Based Actions Aimed at Saving Lives and Preventing Future Generations of Smokers

Efforts to ban menthol cigarettes, ban flavored cigars build on previous flavor ban and mark significant steps to reduce addiction and youth experimentation, improve quitting, and address health disparities

Today, the U.S. Food and Drug Administration announced it is committing to advancing two tobacco product standards to significantly reduce disease and death from using combusted tobacco products, the leading cause of preventable death in the U.S. The FDA is working toward issuing proposed…

Read the Full Article…

More

CSAM Newsletter – Vol. 45 Issue #2 (Winter 2020)

The Newest Issue of the CSAM Newsletter is available. If you haven’t seen it yet, CLICK HERE to read it!

This issue features the President’s message by CSAM President, Anthony Albanese; 2020 Public Policy Report; and Updates from the Education Committee!

The ABPM & ASAM Announce a Four-Year Extension of the Practice Pathway for Addiction Medicine

Chicago, IL, November 30, 2020: The American Board of Preventive Medicine (ABPM) and the American Society of Addiction Medicine (ASAM) jointly announced today the American Board of Medical Specialties’ (ABMS) approval of a four-year extension of the practice…

Click Here to Read the entire article.

DEA Issues Interim Final Rule Clarifying MAT Dispensing

The Drug Enforcement Administration (DEA) issued an Interim Final Rule to clarify sections of the 2018 SUPPORT for Patients and Communities Act. The provisions in the Rule seek to further expand providers’ abilities to prescribe medication assisted treatment (MAT) to individuals suffering from opioid use disorders.

Key items addressed in the Rule include:

  1. Providers can prescribe MAT for up to 100 patients immediately, if the provider holds credentialing in addiction medicine or provides MAT using covered medications in a qualified practice setting. This updates prior rules which mandated a waivered provider could only treat up to 30 patients in their first year of the waiver before applying to treat up to 100 patients.
  2. Nurse practitioners and physician assistants had previously been granted the ability to be waivered to prescribe MAT on a temporary basis. The Interim Final Rule made this provision permanent.
  3. The definition of a “qualifying provider” eligible to prescribe MAT was expanded to include clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives. These providers are eligible to prescribe MAT on a temporary basis, through October 1, 2023. Waivered providers are eligible to treat up to 30 patients.
  4. A physician is eligible to receive a waiver to prescribe MAT if the physician recently graduated from a medical school that included at least 8 hours of training on treating and managing opioid-dependent patients.This shifts new waivers from post-residency continuing medical education to medical school or residency training.
  5. Pharmacies can permanently provide medications for maintenance or detoxification treatment to providers’ registered locations for use in treatment. Pharmacies previously were only allowed to deliver medications to the ultimate user or research subject.

Please send feedback on the Interim Final Rule to Chris Regal (cregal@ahip.org) by December 3. We will circulate draft comments prior to the December 10 Opioid Addiction Prevention and Treatment Work Group meeting. 

We look forward to your feedback. Please be in touch with questions. Thank you.

Article provided by AHIP.

Press Release: Gov. Newsom, Lt. Gov. Kounalakis To California: Beware Big Tobacco’s Lies and Deception to Overturn Landmark Law to Protect Kids

Click Here to read the Press Release.